Document Detail


Pharmacokinetic optimization of antiretroviral therapy in pregnancy.
MedLine Citation:
PMID:  23018528     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Antiretroviral therapy suppresses replication of HIV allowing restoration and/or preservation of the immune system. Providing combination antiretroviral therapy during pregnancy can treat maternal HIV infection and/or reduce perinatal HIV transmission. However, providing treatment to pregnant women is challenging due to physiological changes that can alter antiretroviral pharmacokinetics. Suboptimal drug exposure can result in HIV RNA rebound, the selection of resistant virus or an increased risk of HIV-1 transmission to the infant. Increased drug exposure can produce unwarranted maternal adverse effects and/or fetal toxicity. Subsequently, dose adjustments may be necessary during pregnancy to achieve comparable antiretroviral exposure to non-pregnant adults. For several antiretrovirals, systemic exposure is decreased during the last trimester of pregnancy. By 6-12 weeks postpartum, concentrations return to those prior to pregnancy. Also, the extent of antiretroviral placental transfer to the fetus and degree of antiretroviral excretion into breast milk varies within, and between, antiretroviral drug classes. It is necessary to consider the pharmacological characteristics of each antiretroviral when optimizing combination therapy during pregnancy to treat maternal HIV infection and prevent perinatal HIV transmission.
Authors:
Kajal Buckoreelall; Tim R Cressey; Jennifer R King
Related Documents :
24664798 - Long-term health outcomes in offspring born to women with diabetes in pregnancy.
6359068 - Diabetes mellitus and pregnancy.
15177668 - The development of large intestine during the fetal period.
8008578 - Resuscitation in special circumstances.
1855608 - Intra-uterine hematoma in pregnancy.
25151278 - Body image concerns during pregnancy are associated with a shorter breast feeding durat...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical pharmacokinetics     Volume:  51     ISSN:  0312-5963     ISO Abbreviation:  Clin Pharmacokinet     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7606849     Medline TA:  Clin Pharmacokinet     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  639-59     Citation Subset:  IM    
Affiliation:
Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham School of Medicine, 1530 3rd Ave. S., VH156, Birmingham, AL, 35294, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Necessity and risks of arterial blood sampling in healthy volunteer studies.
Next Document:  Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.